Most Read Articles
Stephen Padilla, 25 Jul 2019
Nonvitamin K antagonist oral anticoagulants (NOACs) appear to confer more clinical benefits to elderly patients with atrial fibrillation (AF) than vitamin K antagonist anticoagulants (VKAs), suggests a study, adding that this is primarily driven by the lower rates of major bleeding.
22 Aug 2018
In patients with atrial fibrillation (AF) naïve to oral anticoagulants (OACs), standard-dose nonvitamin K antagonist OACs (NOACs) provides better survival benefits than warfarin, a recent meta-analysis has shown.
Stephen Padilla, 31 Aug 2018
Treatment with rivaroxaban results in less recurrent venous thromboembolism (VTE) in frail patients with VTE, with similar good bleeding outcomes, compared with warfarin, reports a study.
Stephen Padilla, 11 Sep 2018
Use of diclofenac, a traditional nonsteroidal anti-inflammatory drug (NSAID) with cyclo-oxygenase-2 (COX-2) selectivity similar to COX-2 inhibitors, is associated with higher cardiovascular health risk compared with nonuse, paracetamol use and use of other traditional NSAIDs, a recent study has shown.

Beta-blockers safe for use in ECMO patients

10 Aug 2019

The use of beta-blockers in hypoxaemic patients receiving veno-venous extracorporeal membrane oxygenation (V–V ECMO) safely and modestly increases oxygen saturation, a recent study has found.

Researchers retrospectively examined 33 patients (median age, 49 years; 55 percent male) who received beta-blockers for a median of 4 days while on V–V ECMO. The primary safety outcome was the occurrence of a composite of bradycardia or hypotension requiring intervention, as well as the need for resuscitation, the discontinuation of beta-blockers during the first 5 days and an unexplained spike in serum lactate.

A total of 15 safety events in 13 patients (39 percent) were reported. Majority (n=9) required an increase in norepinephrine dose though only one had to discontinue beta-blocker medication. Other safety endpoints included bradycardia with need for intervention (n=2), new rise in lactate levels (n=2), new septic shock (n=1) and the risk of adverse drug interactions (n=1).

In terms of efficacy, there was a significant increase in oxygen saturation in the first 12 hours after beta-blocker initiation (92 percent to 96 percent; p=0.01) accompanied by a decrease in heart rate (105 to 93 bpm; p<0.01). There were no such changes in lactate levels, norepinephrine dose and mean arterial pressure.

“In our experience, [beta-blocker] therapy was well tolerated and resulted in a significant increase in arterial oxygenation in patients on V-V ECMO,” said researchers. “Future prospective studies should be performed to clarify the benefit of this strategy in this setting.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 25 Jul 2019
Nonvitamin K antagonist oral anticoagulants (NOACs) appear to confer more clinical benefits to elderly patients with atrial fibrillation (AF) than vitamin K antagonist anticoagulants (VKAs), suggests a study, adding that this is primarily driven by the lower rates of major bleeding.
22 Aug 2018
In patients with atrial fibrillation (AF) naïve to oral anticoagulants (OACs), standard-dose nonvitamin K antagonist OACs (NOACs) provides better survival benefits than warfarin, a recent meta-analysis has shown.
Stephen Padilla, 31 Aug 2018
Treatment with rivaroxaban results in less recurrent venous thromboembolism (VTE) in frail patients with VTE, with similar good bleeding outcomes, compared with warfarin, reports a study.
Stephen Padilla, 11 Sep 2018
Use of diclofenac, a traditional nonsteroidal anti-inflammatory drug (NSAID) with cyclo-oxygenase-2 (COX-2) selectivity similar to COX-2 inhibitors, is associated with higher cardiovascular health risk compared with nonuse, paracetamol use and use of other traditional NSAIDs, a recent study has shown.